ZA200303668B - Fatty acid analogues for the treatment of inflammatory and autoimmune disorders. - Google Patents

Fatty acid analogues for the treatment of inflammatory and autoimmune disorders. Download PDF

Info

Publication number: ZA200303668B
Authority: ZA; South Africa
Prior art keywords: carbon; alkyl; fatty acid; acid analogues; proviso
Prior art date: 2000-11-28

Application number

ZA200303668A

Other languages

English (en)

Inventor

Rolf Berge

Pal Aukrust

Original Assignee

Thia Medica As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-28

Filing date

2003-05-13

Publication date

2004-01-30

2003-05-13 Application filed by Thia Medica As filed Critical Thia Medica As

2004-01-30 Publication of ZA200303668B publication Critical patent/ZA200303668B/en

Links

235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 21
229930195729 fatty acid Natural products 0.000 title claims abstract description 21
239000000194 fatty acid Substances 0.000 title claims abstract description 21
150000004665 fatty acids Chemical class 0.000 title claims abstract description 21
208000027866 inflammatory disease Diseases 0.000 title claims abstract description 14
238000011282 treatment Methods 0.000 title claims description 13
230000002757 inflammatory effect Effects 0.000 title claims description 12
208000023275 Autoimmune disease Diseases 0.000 title claims description 9
IPBCWPPBAWQYOO-UHFFFAOYSA-N 2-(tetradecylthio)acetic acid Chemical compound CCCCCCCCCCCCCCSCC(O)=O IPBCWPPBAWQYOO-UHFFFAOYSA-N 0.000 claims abstract description 47
238000000034 method Methods 0.000 claims abstract description 14
241000124008 Mammalia Species 0.000 claims abstract description 12
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 5
201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract description 5
208000004732 Systemic Vasculitis Diseases 0.000 claims abstract description 4
206010047115 Vasculitis Diseases 0.000 claims abstract description 4
201000001981 dermatomyositis Diseases 0.000 claims abstract description 4
208000005987 polymyositis Diseases 0.000 claims abstract description 4
LUQGQZIVDLUXLE-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(O)=[Se] Chemical compound CCCCCCCCCCCCCCCC(O)=[Se] LUQGQZIVDLUXLE-UHFFFAOYSA-N 0.000 claims abstract description 3
201000009594 Systemic Scleroderma Diseases 0.000 claims abstract 3
206010042953 Systemic sclerosis Diseases 0.000 claims abstract 3
229910052799 carbon Inorganic materials 0.000 claims description 49
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 46
108090000174 Interleukin-10 Proteins 0.000 claims description 43
102000003814 Interleukin-10 Human genes 0.000 claims description 42
229940076144 interleukin-10 Drugs 0.000 claims description 42
150000001875 compounds Chemical class 0.000 claims description 30
125000000217 alkyl group Chemical group 0.000 claims description 20
108010002350 Interleukin-2 Proteins 0.000 claims description 17
102000000588 Interleukin-2 Human genes 0.000 claims description 17
108700012920 TNF Proteins 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 14
230000001404 mediated effect Effects 0.000 claims description 12
150000001345 alkine derivatives Chemical class 0.000 claims description 11
230000001363 autoimmune Effects 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 8
150000001336 alkenes Chemical class 0.000 claims description 7
230000002708 enhancing effect Effects 0.000 claims description 7
102000000589 Interleukin-1 Human genes 0.000 claims description 6
108010002352 Interleukin-1 Proteins 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 5
125000004423 acyloxy group Chemical group 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 5
125000004414 alkyl thio group Chemical group 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
210000004962 mammalian cell Anatomy 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 4
206010009887 colitis Diseases 0.000 claims description 4
239000000651 prodrug Substances 0.000 claims description 4
229940002612 prodrug Drugs 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
206010043778 thyroiditis Diseases 0.000 claims description 4
206010062269 Adrenalitis Diseases 0.000 claims description 3
206010002388 Angina unstable Diseases 0.000 claims description 3
206010003210 Arteriosclerosis Diseases 0.000 claims description 3
206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
208000024172 Cardiovascular disease Diseases 0.000 claims description 3
206010012438 Dermatitis atopic Diseases 0.000 claims description 3
208000017701 Endocrine disease Diseases 0.000 claims description 3
208000004262 Food Hypersensitivity Diseases 0.000 claims description 3
206010016946 Food allergy Diseases 0.000 claims description 3
206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
206010019280 Heart failures Diseases 0.000 claims description 3
208000009525 Myocarditis Diseases 0.000 claims description 3
208000012902 Nervous system disease Diseases 0.000 claims description 3
208000025966 Neurological disease Diseases 0.000 claims description 3
208000007718 Stable Angina Diseases 0.000 claims description 3
208000007814 Unstable Angina Diseases 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
230000001154 acute effect Effects 0.000 claims description 3
208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
201000008937 atopic dermatitis Diseases 0.000 claims description 3
230000001684 chronic effect Effects 0.000 claims description 3
235000020932 food allergy Nutrition 0.000 claims description 3
201000004332 intermediate coronary syndrome Diseases 0.000 claims description 3
201000006417 multiple sclerosis Diseases 0.000 claims description 3
201000008383 nephritis Diseases 0.000 claims description 3
210000000056 organ Anatomy 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
208000017520 skin disease Diseases 0.000 claims description 3
238000002054 transplantation Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
125000002009 alkene group Chemical group 0.000 claims 2
-1 Ci-C Chemical group 0.000 claims 1
230000001629 suppression Effects 0.000 claims 1
230000000694 effects Effects 0.000 description 26
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 25
102000004127 Cytokines Human genes 0.000 description 21
108090000695 Cytokines Proteins 0.000 description 21
230000003110 anti-inflammatory effect Effects 0.000 description 12
239000002158 endotoxin Substances 0.000 description 12
230000035755 proliferation Effects 0.000 description 12
229920006008 lipopolysaccharide Polymers 0.000 description 11
210000004027 cell Anatomy 0.000 description 9
239000006228 supernatant Substances 0.000 description 7
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
239000011669 selenium Substances 0.000 description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
230000001028 anti-proliverative effect Effects 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
102000003390 tumor necrosis factor Human genes 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000003466 anti-cipated effect Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000000994 depressogenic effect Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000006213 negative regulation of lymphocyte proliferation Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229910052711 selenium Inorganic materials 0.000 description 2
239000000243 solution Substances 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
102100039065 Interleukin-1 beta Human genes 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000581002 Murex Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
108010047620 Phytohemagglutinins Proteins 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000006045 Spondylarthropathies Diseases 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000003969 blast cell Anatomy 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000000212 effect on lymphocytes Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
208000010227 enterocolitis Diseases 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
230000031261 interleukin-10 production Effects 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000012454 limulus amebocyte lysate test Methods 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
230000001885 phytohemagglutinin Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
KYEKHFSRAXRJBR-UHFFFAOYSA-M potassium;selenocyanate Chemical compound [K+].[Se-]C#N KYEKHFSRAXRJBR-UHFFFAOYSA-M 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
201000005671 spondyloarthropathy Diseases 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
206010047470 viral myocarditis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Virology (AREA)
Transplantation (AREA)

ZA200303668A 2000-11-28 2003-05-13 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders. ZA200303668B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NO20006008A NO20006008L (no)	2000-11-28	2000-11-28	Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer

Publications (1)

Publication Number	Publication Date
ZA200303668B true ZA200303668B (en)	2004-01-30

Family

ID=19911849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200303668A ZA200303668B (en)	2000-11-28	2003-05-13	Fatty acid analogues for the treatment of inflammatory and autoimmune disorders.

Country Status (17)

Country	Link
US (2)	US8088825B2 (fr)
EP (1)	EP1351672B1 (fr)
JP (1)	JP4368579B2 (fr)
KR (1)	KR100905335B1 (fr)
CN (1)	CN1296039C (fr)
AT (1)	ATE432071T1 (fr)
AU (2)	AU2316202A (fr)
BR (1)	BR0115527A (fr)
CA (1)	CA2457925C (fr)
DE (1)	DE60138834D1 (fr)
ES (1)	ES2326159T3 (fr)
MX (1)	MXPA03004427A (fr)
NO (1)	NO20006008L (fr)
NZ (1)	NZ525889A (fr)
RU (1)	RU2259823C2 (fr)
WO (1)	WO2002043728A1 (fr)
ZA (1)	ZA200303668B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO328803B1 (no)	2000-03-03	2010-05-18	Thia Medica	Nye fettsyreanaloger
CA2490121C (fr)	2002-06-20	2013-01-08	Ic Vec Limited	Phospholipides modifies
AU2005209331A1 (en) *	2004-01-30	2005-08-11	Peplin Biolipids Pty Ltd	Therapeutic and carrier molecules
KR20070054637A (ko) *	2004-07-19	2007-05-29	티아 메디카 에이에스	식물유 및/또는 어유 및 비-산화성 지방산 구성요소를포함하는 조성물
WO2009006668A1 (fr) *	2007-02-05	2009-01-15	Children, Youth And Women's Health Service	Modulateurs de la prolifération des lymphocytes t dépendante d'un antigène
DE102011050519A1 (de) *	2011-05-20	2012-11-22	Universität Rostock	Alkylschwefelalkansäurederivate und ihre pharmazeutisch verträglichen Salze zur Behandlung chronisch entzündlicher Erkrankungen
AU2014228387B2 (en)	2013-03-11	2016-09-01	Sciadonics, Inc.	Lipid compositions containing bioactive fatty acids
EP2968568A2 (fr)	2013-03-11	2016-01-20	Life Science Nutrition AS	Lipides naturels contenant des acides gras non oxydables
EP3661600A4 (fr)	2017-10-23	2021-08-11	Epitracker, Inc.	Analogues d'acides gras et leur utilisation dans le traitement des états liés au syndrome métabolique
AU2019274431B2 (en)	2018-05-23	2025-03-13	Epitracker, Inc.	Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3908374A4 (fr)	2019-01-09	2022-12-28	Epitracker, Inc.	Compositions et méthodes pour le diagnostic et le traitement de maladies neurodégénératives
JP7404382B2 (ja)	2019-03-04	2023-12-25	エピトラッカーインコーポレイテッド	脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
WO2023080939A1 (fr)	2021-11-03	2023-05-11	Epitracker, Inc.	Pentadécanoylcarnitine pour le traitement d'affections liées à la qualité du vieillissement et à la longévité

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS56164120A (en) *	1980-05-22	1981-12-17	Chisso Corp	Antitumor agent
FR2631339B1 (fr) *	1988-05-10	1990-11-16	Cird	Nouveaux eicosanoides sulfures et leur application en pharmacie et en cosmetique
DE4120917A1 (de) *	1991-06-25	1993-01-07	Basf Ag	Ester von fettsaeuren mit aminoalkoholen zur verwendung bei der bekaempfung von krankheiten
US5807884A (en) *	1992-10-30	1998-09-15	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5618955A (en) *	1992-11-30	1997-04-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en)	1992-11-30	1997-02-18	Yissum Res & Dev	Fatty acid and pharmaceutical compositions containing them
CN1088058C (zh) *	1994-10-13	2002-07-24	肽技术有限公司	经修饰的多不饱和脂肪酸
NO952796D0 (no) *	1995-07-14	1995-07-14	Rolf Berge	Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
RU2089179C1 (ru) *	1995-12-14	1997-09-10	Закрытое акционерное общество "ВАМ"	Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
WO1997038688A1 (fr) *	1996-04-12	1997-10-23	Peptide Technology Pty. Limited	Procedes permettant de traiter des immunopathologies au moyen d'acides gras polyinsatures
IL121165A0 (en) *	1997-06-26	1997-11-20	Yissum Res Dev Co	Pharmaceutical compositions containing carboxylic acids and derivatives thereof
AU7240398A (en) *	1998-05-08	1999-11-29	Rolf Berge	Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
AUPQ291499A0 (en)	1999-09-17	1999-10-07	Women's And Children's Hospital Adelaide	Novel nitro and sulphur containing compounds

2000
- 2000-11-28 NO NO20006008A patent/NO20006008L/no not_active Application Discontinuation
2001
- 2001-11-27 ES ES01998347T patent/ES2326159T3/es not_active Expired - Lifetime
- 2001-11-27 DE DE60138834T patent/DE60138834D1/de not_active Expired - Lifetime
- 2001-11-27 KR KR1020037007097A patent/KR100905335B1/ko not_active Expired - Fee Related
- 2001-11-27 NZ NZ525889A patent/NZ525889A/en unknown
- 2001-11-27 EP EP01998347A patent/EP1351672B1/fr not_active Expired - Lifetime
- 2001-11-27 CA CA2457925A patent/CA2457925C/fr not_active Expired - Fee Related
- 2001-11-27 CN CNB018196969A patent/CN1296039C/zh not_active Expired - Fee Related
- 2001-11-27 BR BR0115527-0A patent/BR0115527A/pt not_active IP Right Cessation
- 2001-11-27 US US10/416,378 patent/US8088825B2/en not_active Expired - Fee Related
- 2001-11-27 MX MXPA03004427A patent/MXPA03004427A/es active IP Right Grant
- 2001-11-27 AT AT01998347T patent/ATE432071T1/de not_active IP Right Cessation
- 2001-11-27 RU RU2003115423/15A patent/RU2259823C2/ru not_active IP Right Cessation
- 2001-11-27 JP JP2002545699A patent/JP4368579B2/ja not_active Expired - Fee Related
- 2001-11-27 AU AU2316202A patent/AU2316202A/xx active Pending
- 2001-11-27 AU AU2002223162A patent/AU2002223162B2/en not_active Ceased
- 2001-11-27 WO PCT/NO2001/000470 patent/WO2002043728A1/fr not_active Ceased
2003
- 2003-05-13 ZA ZA200303668A patent/ZA200303668B/en unknown
2011
- 2011-12-29 US US13/340,157 patent/US20120101161A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1351672B1 (fr)	2009-05-27
BR0115527A (pt)	2003-09-23
HK1073793A1 (en)	2005-10-21
CA2457925C (fr)	2013-03-26
US8088825B2 (en)	2012-01-03
CA2457925A1 (fr)	2002-06-06
US20120101161A1 (en)	2012-04-26
NO20006008L (no)	2002-05-29
MXPA03004427A (es)	2004-05-04
CN1633284A (zh)	2005-06-29
CN1296039C (zh)	2007-01-24
KR100905335B1 (ko)	2009-07-01
US20050165103A1 (en)	2005-07-28
EP1351672A1 (fr)	2003-10-15
AU2002223162B2 (en)	2006-11-30
RU2259823C2 (ru)	2005-09-10
JP4368579B2 (ja)	2009-11-18
NZ525889A (en)	2004-10-29
ATE432071T1 (de)	2009-06-15
NO20006008D0 (no)	2000-11-28
DE60138834D1 (de)	2009-07-09
ES2326159T3 (es)	2009-10-02
AU2316202A (en)	2002-06-11
WO2002043728A1 (fr)	2002-06-06
JP2004514693A (ja)	2004-05-20
KR20030055322A (ko)	2003-07-02

Publication	Publication Date	Title
US20120101161A1 (en)	2012-04-26	Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
Das	1991	Interaction (s) between essential fatty acids, eicosanoids, cytokines, growth factors and free radicals: relevance to new therapeutic strategies in rheumatoid arthritis and other collagen vascular diseases
Allen et al.	1993	Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis.
KR102102677B1 (ko)	2020-04-22	포르볼 에스테르의 조성물
Mohammadian Haftcheshmeh et al.	2021	Immunomodulatory effects of curcumin in rheumatoid arthritis: evidence from molecular mechanisms to clinical outcomes
AU2002223162A1 (en)	2002-08-15	Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
US6572851B2 (en)	2003-06-03	Method for suppressing or treating drug-induced nephropathy
TW200924741A (en)	2009-06-16	Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells
JP4234439B2 (ja)	2009-03-04	Ｉｌ−１２発現調節剤
CN101610765A (zh)	2009-12-23	用于治疗炎症的新组合物
JP2000515111A (ja)	2000-11-14	サイトカインおよび造血因子の内因性産生増強因子とその利用方法
JPH03501382A (ja)	1991-03-28	組換えコロニー刺激因子‐１の使用
EP2001482B1 (fr)	2016-08-24	2-méthoxyestradiol présentant une activité anti-arthritique pouvant modifier l'évolution de la maladie
WO2024035859A1 (fr)	2024-02-15	Polythérapies pour le traitement d'une inflammation
NO324557B1 (no)	2007-11-19	Anvendelse av fettsyreanaloger for a hindre og/eller behandle inflammatoriske og/eller autoimmune forstyrrelser.
CN101668521A (zh)	2010-03-10	用于治疗炎症的新组合物
Ramana et al.	2011	Current prospective of aldose reductase inhibition in the therapy of allergic airway inflammation in asthma
RU2758536C1 (ru)	2021-10-29	Способ снижения воспалительной гиперактивации нейтрофилов
WO2024035864A1 (fr)	2024-02-15	Association de quercétine et de pathénolide en tant qu'agents anti-inflammatoires à utiliser dans le traitement de la dermatite
Knisely et al.	1994	Production of interleukin-6 and granulocyte-macrophage colony-stimulating factor by murine iris and ciliary body explants.
WO2002056911A1 (fr)	2002-07-25	Inhibiteurs du rejet d'organes transplantes
HK1073793B (en)	2007-07-06	Fatty acid analogues for the treatment of inflammatory and autoimmune disorders